AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

In a report released today, Emily Field from Barclays maintained a Buy rating on AbbVie, with a price target of $300.00. According to TipRanks, Fie...

Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s first-in-human Phase 1 trial, officially titled “A First-In-Human Stud...

AbbVie’s ABBV-722 Phase 1 Milestone: What Early Safety Data Means for Investors

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has completed a real-world study called “Real-world Effectiveness and Tr...

AbbVie Wraps Up Real-World RINVOQ Study in Psoriatic Arthritis: What Investors Should Watch

Stocks ended the week mixed as strength in blue-chip shares offset losses in technology and semiconductor stocks. The Dow Jones Industrial Average ...

The Week That Was, The Week Ahead: Macro and Markets, July 26

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has launched a new Phase 1 study called “A Phase 1, Randomized, Double-B...

AbbVie’s ABBV-313 Phase 1 Trial: What Early Safety Work Means for Investors

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Integer Holdings (ITGR), Thermo Fisher (TMO) and A...

Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Thermo Fisher (TMO) and AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s latest Phase 1 update centers on how its drug ABBV-8736 moves through ...

AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV) with b...

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Stocks ended the week higher as continued enthusiasm for AI and technology shares helped lift the major U.S. indexes. The Dow Jones Industrial Aver...

The Week That Was, The Week Ahead: Macro and Markets, July 12

AbbVie ($ABBV) and Abbott Laboratories ($ABT) are two Dividend Aristocrat stocks with a Strong Buy consensus rating on Wall Street and an ex-divide...

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and Eli Lilly & Co (LLY) with bullish ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY)

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie, with a price target of $295.00. The company’s shar...

Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tyra Bioscience (TYRA), Corcept Therapeutics (CORT) ...

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Corcept Therapeutics (CORT)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a first‑in‑human study called “A First‑in‑Human Sin...

AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. Chen covers the Healthcare sector, focusi...

Scotiabank Sticks to Its Buy Rating for AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s latest update covers a post‑market study on its CoolSculpting Elite de...

AbbVie’s CoolSculpting Elite Study Update Strengthens Aesthetics Outlook

Abbvie ($ABBV) announced an update on their ongoing clinical study. The Phase 2 trial NCT05660967 tests epcoritamab with or without lenalidomide as...

Trial Termination Shifts Outlook for AbbVie’s Epcoritamab in Frontline Lymphoma

Abbvie ($ABBV) announced an update on their ongoing clinical study. The FAST study, officially titled “Evaluation of Function And Satisfaction of U...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$263.53	+0.12%	3.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$263.53	+0.1%	3.66M
3
4
5
6

ABBV

ABBV

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel